Ginkgo biloba extract (EGb761®) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment

Pharmacological Research

Volumn 60, Issue 1, 2009, Pages 68-73

  Fehske, Christian J ^a   Leuner, Kristina ^a   Müller, Walter E ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

EGb761 ; Ginkgo biloba extract; MAO activity; Monoaminergic neurotransmission; Norepinephrine uptake

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BIOGENIC AMINE; DOPAMINE; DOPAMINE TRANSPORTER; GINKGO BILOBA EXTRACT; NORADRENALIN; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FRONTAL CORTEX; MONOAMINERGIC SYSTEM; MOUSE; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; SYNAPTOSOME;

ADMINISTRATION, ORAL; ANIMALS; COGNITION; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; MICE, INBRED STRAINS; MONOAMINE OXIDASE; NOREPINEPHRINE; PLANT EXTRACTS; RATS; RATS, WISTAR; SEROTONIN; SYNAPTIC TRANSMISSION; SYNAPTOSOMES;

EID: 67349099191     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.02.012     Document Type: Article

References (47)

1. DeFeudis F.V. A brief history of EGb 761 and its therapeutic uses. Pharmacopsychiatry 36 Suppl. 1 (2003) S2-S7
2. Zimmermann M., Colciaghi F., Cattabeni F., and Di Luca M. Ginkgo biloba extract: from molecular mechanisms to the treatment of Alzheimer's disease. Cell Mol Biol (Noisy-le-grand) 4848 (2002) 613-623
3. Le Bars P.L., Katz M.M., Berman N., Itil T.M., Freedman A.M., and Schatzberg A.F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278278 (1997) 1327-1332
4. Le Bars P.L., Kieser M., and Itil K.Z. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord 1111 (2000) 230-237
5. Kanowski S., Herrmann W.M., Stephan K., Wierich W., and Horr R. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 2929 (1996) 47-56
6. Napryeyenko O., and Borzenko I. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung 5757 (2007) 4-11
7. Schneider L.S., DeKosky S.T., Farlow M.R., Tariot P.N., Hoerr R., and Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 22 (2005) 541-551
8. Birks J., and Grimley E.J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (2007) CD003120
9. Abdel-Kader R., Hauptmann S., Keil U., Scherping I., Leuner K., Eckert A., et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res 5656 (2007) 493-502
10. Eckert A., Keil U., Scherping I., Hauptmann S., and Muller W.E. Stabilization of mitochondrial membrane potential and improvement of neuronal energy metabolism by Ginkgo biloba extract EGb 761. Ann N Y Acad Sci 10561056 (2005) 474-485
11. Sastre J., Millan A., Garcia dlA, Pla R., Juan G., Pallardo, et al. A Ginkgo biloba extract (EGb 761) prevents mitochondrial aging by protecting against oxidative stress. Free Radic Biol Med 2424 (1998) 298-304
12. Luo Y., Smith J.V., Paramasivam V., Burdick A., Curry K.J., Buford J.P., et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 9999 (2002) 12197-12202
13. Bastianetto S., Ramassamy C., Dore S., Christen Y., Poirier J., and Quirion R. The Ginkgo bilobaextract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 1212 (2000) 1882-1890
14. Stoll S., Scheuer K., Pohl O., and Muller W.E. Ginkgo biloba extract (EGb 761) independently improves changes in passive avoidance learning and brain membrane fluidity in the aging mouse. Pharmacopsychiatry 2929 (1996) 144-149
15. Ramassamy C., Girbe F., Christen Y., and Costentin J. Ginkgo biloba extract EGb 761 or trolox C prevent the ascorbic acid/Fe2+ induced decrease in synaptosomal membrane fluidity. Free Radic Res Commun 1919 (1993) 341-350
16. Smith J.V., and Luo Y. Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761. J Alzheimer's Dis 55 (2003) 287-300
17. Hauptmann S., Keil U., Scherping I., Bonert A., Eckert A., and Muller W.E. Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease. Exp Gerontol 4141 (2006) 668-673
18. Eckert A., Keil U., Marques C.A., Bonert A., Frey C., Schussel K., et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol 6666 (2003) 1627-1634
19. Maclennan K.M., Darlington C.L., and Smith P.F. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol 6767 (2002) 235-257
20. DeFeudis F.V., and Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 11 (2000) 25-58
21. Muller W.E., and Chatterjee S.S. Cognitive and other behavioral effects of EGb 761 in animal models. Pharmacopsychiatry 36 Suppl. 1 (2003) S24-S31
22. Sloley B.D., Urichuk L.J., Morley P., Durkin J., Shan J.J., Pang P.K., et al. Identification of kaempferol as a monoamine oxidase inhibitor and potential neuroprotectant in extracts of Ginkgo biloba leaves. J Pharm Pharmacol 5252 (2000) 451-459
23. ®) on levels of dopamine, noradrenaline and serotonin in the prefrontal cortex of the awake rat. Planta Med 7272 (2006) 961-1089
24. Ramassamy C., Christen Y., Clostre F., and Costentin J. The Ginkgo bilobaextract, EGb761, increases synaptosomal uptake of 5-hydroxytryptamine: in-vitro and ex-vivo studies. J Pharm Pharmacol 4444 (1992) 943-945
25. White H.L., Scates P.W., and Cooper B.R. Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. Life Sci 5858 (1996) 1315-1321
26. Wu W.R., and Zhu X.Z. Involvement of monoamine oxidase inhibition in neuroprotective and neurorestorative effects of Ginkgo bilobaextract against MPTP-induced nigrostriatal dopaminergic toxicity in C57 mice. Life Sci 6565 (1999) 157-164
27. Fowler J.S., Wang G.J., Volkow N.D., Logan J., Franceschi D., Franceschi M., et al. Evidence that Ginkgo bilobaextract does not inhibit MAO A and B in living human brain. Life Sci 6666 (2000) L141-L146
28. Muller W.E., Rolli M., Schafer C., and Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 30 Suppl. 2 (1997) 102-107
29. Brunello N., Racagni G., Clostre F., Drieu K., and Braquet P. Effects of an extract of Ginkgo biloba on noradrenergic systems of rat cerebral cortex. Pharmacol Res Commun 1717 (1985) 1063-1072
30. Pardon M.C., Joubert C., Perez-Diaz F., Christen Y., Launay J.M., and Cohen-Salmon C. In vivo regulation of cerebral monoamine oxidase activity in senescent controls and chronically stressed mice by long-term treatment with Ginkgo biloba extract (EGb 761). Mech Ageing Dev 113113 (2000) 157-168
31. Porsolt R.D., Roux S., and Drieu K. Evaluation of a Ginkgo biloba extract (EGb 761) in functional tests for monoamine oxidase inhibition. Arzneimittelforschung 5050 (2000) 232-235
32. Ramassamy C., Clostre F., Christen Y., and Costentin J. Prevention by a Ginkgo biloba extract (GBE 761) of the dopaminergic neurotoxicity of MPTP. J Pharm Pharmacol 4242 (1990) 785-789
33. Ramassamy C., Naudin B., Christen Y., Clostre F., and Costentin J. Prevention by Ginkgo biloba extract (EGb 761) and trolox C of the decrease in synaptosomal dopamine or serotonin uptake following incubation. Biochem Pharmacol 4444 (1992) 2395-2401
34. Huguet F., and Tarrade T. Alpha 2-adrenoceptor changes during cerebral ageing. The effect of Ginkgo biloba extract. J Pharm Pharmacol 4444 (1992) 24-27
35. In: Angoli A., Rapain J.R., Scapagnini V., and Weitbrecht W.V. (Eds). Effects of Ginkgo biloba extract on organic cerebral impairment (1985), J Libbey, London - Paris pp. 35-42
36. Porsolt R.D., Martin P., Lenegre A., Fromage S., and Drieu K. Effects of an extract of Ginkgo biloba (EGB 761) on "learned helplessness" and other models of stress in rodents. Pharmacol Biochem Behav 3636 (1990) 963-971
37. Hoerr R. Behavioural and psychological symptoms of dementia (BPSD): effects of EGb 761. Pharmacopsychiatry 36 Suppl. 1 (2003) S56-S61
38. Scripnikov A., Khomenko A., and Napryeyenko O. Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wien Med Wochenschr 157 (2007) 295-300
39. Lapiz M.D., Bondi C.O., and Morilak D.A. Chronic treatment with desipramine improves cognitive performance of rats in an attentional set-shifting test. Neuropsychopharmacology 3232 (2007) 1000-1010
40. Arnsten A.F., and Li B.M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 5757 (2005) 1377-1384
41. Stahl S.M. Neurotransmission of cognition. Part 1. Dopamine is a hitchhiker in frontal cortex: norepinephrine transporters regulate dopamine. J Clin Psychiatry 6464 (2003) 4-5
42. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2727 (2002) 699-711
43. Seamans J.K., and Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 7474 (2004) 1-58
44. Bonisch H., and Bruss M. The norepinephrine transporter in physiology and disease. Handbook of experimental pharmacology (2006) pp. 485-524
45. Sakakibara H., Ishida K., Grundmann O., Nakajima J., Seo S., Butterweck V., et al. Antidepressant effect of extracts from Ginkgo biloba leaves in behavioral models. Biochem Pharm Bull 29 (2006) 1767-1770
46. Kalkunte S.S., Gingh A.P., Chaves F.C., Gianfagna T.J., Pundir V.S., Jaiswal A.K., et al. Antidepressant and antistress activity of GC-MS characterized lipophilic extracts of Ginkgo biloba leaves. Phytother Res 21 (2007) 1061-1065
47. Stahl S.M. Neurotransmission of cognition. Part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry 64 2 (2003) 110.1